MuhammadShahzebMunirMDMPH, MS(He/Him)

Internal Medicine • Atlanta, GA

Hospital Medicine/Hospitalist, Preventive Medicine

Principal Investigator

Join to view full profile

Dr. Munir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Munir's full profile

Already have an account?

Office
6065 Roswell Rd NE
Atlanta, GA 30328
Is this information wrong?

Summary

I am a full time Principal Investigator on Industry Sponsored Clinical Trials and a part time Internist / Hospitalist.

Clinical Expertise

General preventive medicine, Hospitalist medicine, Clinical research

Education & Training

Univeristy of WisconsinMS, Biotechnology, 2019 - 2021
Mayo Clinic College of Medicine and Science (Rochester)Residency, Public Health and General Preventive Medicine, 2011 - 2013
University of MinnesottaMPH, Public Health, 2011 - 2013
Wellspan Health/York HospitalResidency, Internal Medicine, 2008 - 2010
University of Maryland Medical Center Midtown CampusInternship, Internal Medicine, 2007 - 2008
University of Medicine and Pharmacy ‘Gr T Popa” Iasi Class of 2001

Certifications & Licensure

WI State Medical License 2013 - 2025
GA State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Preventive Medicine Public Health & General Preventive Medicine

Awards, Honors, & Recognition

Distinguished Service Award Preventive Medicine Residency Program, SMPH, UW Madison, 2018

Clinical Trials

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Start of enrollment: 2022 Dec 29
Recruiting
Phase 3
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older Start of enrollment: 2021 Jul 21
Completed
Phase 3
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above Start of enrollment: 2021 May 25
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 Start of enrollment: 2020 Dec 27
Completed
Phase 3
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older Start of enrollment: 2021 May 26
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Start of enrollment: 2021 Feb 22
Active, not recruiting
Phase 3
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) Start of enrollment: 2020 May 20
Completed
Phase 2, Phase 3
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE Start of enrollment: 2020 Sep 04
Active, not recruiting
Phase 4
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm Start of enrollment: 2020 May 02
Completed
Phase 3
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Start of enrollment: 2021 Dec 15
Active, not recruiting
Phase 3
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Start of enrollment: 2023 Apr 17
Active, not recruiting
Phase 3
A Study of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age Start of enrollment: 2023 Oct 19
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

18 citations
Silent myocardial ischemia: Current perspectives and future directions.
A.H. Ahmed, Shankar K, Eftekhari H, M.S. Munir, Robertson J, A.M. Brewer, Stupin, Casscells Sw> ;Experimental and Clinical Cardiology. 2007 Jan 1
2 citations
Devices in heart failure: potential methods for device-based monitoring of congestive heart failure.
Shahzeb M. Munir, Roberta C. Bogaev, Ed Sobash, K.J. Shankar, Sreedevi Gondi, Igor V. Stupin, Jillian Robertson, M Alan Brewer, S. Ward Casscells, Reynolds M. Delgado,...> ;Texas Heart Institute Journal. 2008 Jan 1
Sirolimus-eluting stents versus bare-metal stents in routine clinical use: a nonrandomized comparison.
Munir M, Aliota J, Ahmed A, Mohammed A, Lee VV, Elayda MA, Wilson JM> ;Texas Heart Institute journal.
7 citations
Genetic Markers Associated With Plasma Protein C Level in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study
M. Shahzeb Munir, Lu-Chen Weng, Weihong Tang, Saonli Basu, James S. Pankow, Nena Matijevic, Mary Cushman, Eric Boerwinkle, Aaron R. Folsom> ;Genetic Epidemiology. 2014 Dec 1
14 citations
The association of 9p21-3 locus with coronary atherosclerosis: a systematic review and meta-analysis
Muhammad S Munir, Zhen Wang, Fares Alahdab, Mark W. Steffen, Patricia J. Erwin, Iftikhar J. Kullo, Mohammad Hassan Murad> ;BMC Medical Genetics. 2014 Jun 6
8 citations
Circadian Body Temperature Variability is an Indicator of Poor Prognosis in Cardiomyopathic Hamsters
Amany Ahmed, Sreedevi Gondi, Casey Cox, Suwei Wang, Igor V. Stupin, K.J. Shankar, Shahzeb M. Munir, Ed Sobash, Alan Brewer, James J. Ferguson, MacArthur A. Elayda, S. ...> ;Journal of Cardiac Failure. 2010 Mar 1
17 citations
Decreasing body temperature predicts early rehospitalization in congestive heart failure.
Amany Ahmed, Ibrahim Aboshady, Shahzeb M. Munir, Sreedevi Gondi, Alan Brewer, S. David Gertz, Dejian Lai, Naushad A. Shaik, K.J. Shankar, Anita Deswal, S. Ward Casscells> ;Journal of Cardiac Failure. 2008 Aug 1
Join now to see all

Journal Articles

Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19
ACTIV-4a Investigators, JAMA Network Open, 5/25/2023
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, ACTIV-4a, and REMAP-CAP Investigators, N Engl J Med 2021; 385:790-802 DOI: 10.1056/NEJMoa2105911, 8/26/2021